A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
Status:
Completed
Trial end date:
2018-10-18
Target enrollment:
Participant gender:
Summary
This is a Phase I open-label study to evaluate the pharmacokinetic (PK) profile of a single
oral dose of vadadustat in subjects with hepatic impairment(HI) compared to healthy matched
control subjects with normal hepatic function.